Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2066

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292066)

This is a description of a pharmaceutical product called NILD. It is a rivastigmine transdermal system that is used for transdermal use only. The system contains 18mg rivastigmine, providing 9.5mg rivastigmine every 24 hours. The patch should be worn for 24 hours and shouldn't be cut. It should be applied immediately to an intact skin after removal from the pouch and the location of each new patch should be changed. The patch should be stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). This product is available in one unit with an NDC number of 63629-2066-1 and is only for Rx use.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

FDA Label Image

Figure 1 (Rivastigmine 02)

FDA Label Image

Figure 2 (Rivastigmine 03)

This is a table providing the concentration of Rivastigmine in ng/mL, under different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, 4.6mg/24 hours) and different number of patients (n=19, n=22, n=22).*

FDA Label Image

Figure 3 (Rivastigmine 04)

FDA Label Image

Figure 4 (Rivastigmine 05)

FDA Label Image

Figure 5 (Rivastigmine 06)

FDA Label Image

Figure 6 (Rivastigmine 07)

FDA Label Image

Figure 7 (Rivastigmine 08)

This appears to be a statistical analysis of the improvement observed in patients receiving Rivastigmine Transdermal System over a period of 8, 16, and 24 weeks of treatment. The analysis compares mean difference and standard errors of the LS means in patients receiving a 5 cm patch versus a 15 cm patch. The results indicate that patients receiving the larger patch showed a significant improvement compared to those who received the smaller patch.*

FDA Label Image

Figure 8 (Rivastigmine 09)

This is a clinical study evaluating the efficacy of Rivastigmine Transdermal System in improving cognitive decline over a period of 16 weeks. The study compares two dosages of the system (15 cm² and 5 cm²) and reports least squares means (LS means) and standard errors of the LS means (STE) obtained through an analysis of covariance model adjusted for pooled center and baseline. The statistical significance at a level of 0.05 is also reported.*

FDA Label Image

Figure A (Rivastigmine 10)

FDA Label Image

Figure B (Rivastigmine 11)

This is a list of body parts where Lenge, Z and Lk have been mentioned along with Left or Right Upper Arm, Left or Right Side of Chest, Left or Right Upper Back and Left or Right Lower Back. It is unclear what Lenge, Z and Lk indicate as the text appears to be incomplete.*

FDA Label Image

Figure C (Rivastigmine 12)

FDA Label Image

Figure D (Rivastigmine 13)

FDA Label Image

Figure E (Rivastigmine 14)

FDA Label Image

Figure F (Rivastigmine 15)

FDA Label Image

Figure G (Rivastigmine 16)

FDA Label Image

Figure H (Rivastigmine 17)

The text appears to be a set of instructions for disposing of a slide folded patch. The patch should be placed in the trash and the sticky sides should be folded together and placed in an empty pouch that has been saved. It also advises to keep the pouch away from children and pets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.